Newborn screening for spinal muscular atrophy: Anticipating an imminent need

Han C. Phan, Jennifer L. Taylor, Harry Hannon, R. Howell

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Spinal muscular atrophy (SMA) is the most common genetic cause of infant mortality. Children with type I SMA typically die by the age of 2 years. Recent progress in gene modification and other innovative therapies suggest that improved outcomes may soon be forthcoming. In animal models, therapeutic intervention initiated before the loss of motor neurons alters SMA phenotype and increases lifespan. Presently, supportive care including respiratory, nutritional, physiatry, and orthopedic management can ameliorate clinical symptoms and improve survival rates if SMA is diagnosed early in life. Newborn screening could help optimize these potential benefits. A recent report demonstrated that SMA detection can be multiplexed at minimal additional cost with the assay for severe combined immunodeficiency, already implemented by many newborn screening programs. The public health community should remain alert to the rapidly changing developments in early detection and treatment of SMA.

Original languageEnglish (US)
Pages (from-to)217-229
Number of pages13
JournalSeminars in Perinatology
Volume39
Issue number3
DOIs
StatePublished - Apr 1 2015

Fingerprint

Spinal Muscular Atrophy
Newborn Infant
Spinal Muscular Atrophies of Childhood
Severe Combined Immunodeficiency
Physical and Rehabilitation Medicine
Investigational Therapies
Infant Mortality
Motor Neurons
Orthopedics
Survival Rate
Animal Models
Public Health
Phenotype
Costs and Cost Analysis
Therapeutics
Genes

Keywords

  • Newborn screening
  • Spinal muscular atrophy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

Newborn screening for spinal muscular atrophy : Anticipating an imminent need. / Phan, Han C.; Taylor, Jennifer L.; Hannon, Harry; Howell, R.

In: Seminars in Perinatology, Vol. 39, No. 3, 01.04.2015, p. 217-229.

Research output: Contribution to journalArticle

Phan, Han C. ; Taylor, Jennifer L. ; Hannon, Harry ; Howell, R. / Newborn screening for spinal muscular atrophy : Anticipating an imminent need. In: Seminars in Perinatology. 2015 ; Vol. 39, No. 3. pp. 217-229.
@article{0345b40ffce449dd955ac3117aa8aae5,
title = "Newborn screening for spinal muscular atrophy: Anticipating an imminent need",
abstract = "Spinal muscular atrophy (SMA) is the most common genetic cause of infant mortality. Children with type I SMA typically die by the age of 2 years. Recent progress in gene modification and other innovative therapies suggest that improved outcomes may soon be forthcoming. In animal models, therapeutic intervention initiated before the loss of motor neurons alters SMA phenotype and increases lifespan. Presently, supportive care including respiratory, nutritional, physiatry, and orthopedic management can ameliorate clinical symptoms and improve survival rates if SMA is diagnosed early in life. Newborn screening could help optimize these potential benefits. A recent report demonstrated that SMA detection can be multiplexed at minimal additional cost with the assay for severe combined immunodeficiency, already implemented by many newborn screening programs. The public health community should remain alert to the rapidly changing developments in early detection and treatment of SMA.",
keywords = "Newborn screening, Spinal muscular atrophy",
author = "Phan, {Han C.} and Taylor, {Jennifer L.} and Harry Hannon and R. Howell",
year = "2015",
month = "4",
day = "1",
doi = "10.1053/j.semperi.2015.03.006",
language = "English (US)",
volume = "39",
pages = "217--229",
journal = "Seminars in Perinatology",
issn = "0146-0005",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Newborn screening for spinal muscular atrophy

T2 - Anticipating an imminent need

AU - Phan, Han C.

AU - Taylor, Jennifer L.

AU - Hannon, Harry

AU - Howell, R.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Spinal muscular atrophy (SMA) is the most common genetic cause of infant mortality. Children with type I SMA typically die by the age of 2 years. Recent progress in gene modification and other innovative therapies suggest that improved outcomes may soon be forthcoming. In animal models, therapeutic intervention initiated before the loss of motor neurons alters SMA phenotype and increases lifespan. Presently, supportive care including respiratory, nutritional, physiatry, and orthopedic management can ameliorate clinical symptoms and improve survival rates if SMA is diagnosed early in life. Newborn screening could help optimize these potential benefits. A recent report demonstrated that SMA detection can be multiplexed at minimal additional cost with the assay for severe combined immunodeficiency, already implemented by many newborn screening programs. The public health community should remain alert to the rapidly changing developments in early detection and treatment of SMA.

AB - Spinal muscular atrophy (SMA) is the most common genetic cause of infant mortality. Children with type I SMA typically die by the age of 2 years. Recent progress in gene modification and other innovative therapies suggest that improved outcomes may soon be forthcoming. In animal models, therapeutic intervention initiated before the loss of motor neurons alters SMA phenotype and increases lifespan. Presently, supportive care including respiratory, nutritional, physiatry, and orthopedic management can ameliorate clinical symptoms and improve survival rates if SMA is diagnosed early in life. Newborn screening could help optimize these potential benefits. A recent report demonstrated that SMA detection can be multiplexed at minimal additional cost with the assay for severe combined immunodeficiency, already implemented by many newborn screening programs. The public health community should remain alert to the rapidly changing developments in early detection and treatment of SMA.

KW - Newborn screening

KW - Spinal muscular atrophy

UR - http://www.scopus.com/inward/record.url?scp=84929671164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929671164&partnerID=8YFLogxK

U2 - 10.1053/j.semperi.2015.03.006

DO - 10.1053/j.semperi.2015.03.006

M3 - Article

C2 - 25979781

AN - SCOPUS:84929671164

VL - 39

SP - 217

EP - 229

JO - Seminars in Perinatology

JF - Seminars in Perinatology

SN - 0146-0005

IS - 3

ER -